1. < Home

urothelial carcinoma

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, Wolchok JD, Ribas A. Tumor dynamics in patients with solid tumors treated[...]

By sjmartinez • September 13, 2023
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma

Hui G, Stefanoudakis D, Zektser Y, Isaacs DJ, Hannigan C, Pantuck AJ, Drakaki A. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in[...]

By sjmartinez • August 26, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska[...]

By sjmartinez • June 30, 2023
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR,[...]

By sjmartinez • October 22, 2022